Needham & Company Starts Generation Bio (GBIO) at Buy

February 18, 2021 7:38 AM EST
Get Alerts GBIO Hot Sheet
Price: $15.46 --0%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 12 | New: 30
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Needham & Company analyst Gil Blum initiates coverage on Generation Bio (NASDAQ: GBIO) with a Buy rating and a price target of $50.00.

The analyst commented, "We believe GBIO is developing a new category of gene therapy with transformative potential for the industry. Gene therapy's ability to repair the underlying genetic cause of a disease offers therapeutic options in some of the most severe indications. However, fundamental challenges abound. Our KOL survey identified gene therapy durability as a key issue with current therapeutics. Generation's platform combines two innovative technologies: close ended DNA plasmids (ceDNA) and cell targeted lipid nanoparticles (ctLNPs). The ceDNA/ctLNP platform can potentially enable re-treatment of patients thus extending the durability of therapy."

For an analyst ratings summary and ratings history on Generation Bio click here. For more ratings news on Generation Bio click here.

Shares of Generation Bio closed at $31.79 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Needham & Company